atomoxetine / Generic mfg. - LARVOL DELTA

Atomoxetine suppresses nitric oxide synthesis induced by lipopolysaccharide in BV-2 microglia cells through the modulation of STAT1 and STAT3. (PubMed, Neuroscience) - "Conversely, while total STAT3 expression was reduced, its phosphorylation ratio increased, reflecting a more complex regulatory interaction. Collectively, these findings suggested that ATX exerts multifaceted effects on key inflammatory signaling pathways, notably modulating iNOS expression through simultaneous regulation of the STAT1 and STAT3."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Inflammation • Psychiatry • NFKBIA • STAT1 • STAT3

AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Radboud University Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Pharmacological management of attention deficit hyperactivity disorder in adults. (PubMed, Aust Prescr) - "The main pharmacotherapies for adults with ADHD include psychostimulants, such as methylphenidate and amphetamines (dexamfetamine and lisdexamfetamine), and non-psychostimulants such as atomoxetine. Individuals prescribed ADHD drugs should be monitored for both physical (e.g. cardiac symptoms, appetite changes, seizures) and psychiatric (e.g. mood disturbances, anxiety, psychosis) adverse effects. While pharmacological treatment is effective for adults with ADHD, it should be integrated into a broader, multidisciplinary approach that also includes nonpharmacological strategies such as psychological therapies and allied health support."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Mood Disorders • Psychiatry

Differentiating atomoxetine-induced agitation from mania relapse in a patient with bipolar disorder and ADHD: a case report. (PubMed, J Psychiatry Neurosci) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Construction of Chiral β-Boryl Aldehydes via Asymmetric Hydroformylation of 1,1-Disubstituted Alkenyl Boronates. (PubMed, Org Lett) - "Scale-up studies delivered TON of up to 4050, underscoring the robustness and practical utility of the method. The synthetic value of the resulting bifunctional products is further showcased through concise derivatizations and formal syntheses of (S)-Fluoxetine and (R)-Atomoxetine, highlighting their potential as versatile, densely functionalized building blocks for complex molecule construction."

Journal

Clinical Features of Adults With Attention Deficit/Hyperactivity Disorder, Focusing on Their Adherence to Medication. (PubMed, Psychiatry Investig) - "ADHD not only persists into adulthood but is associated with a wide range of psychiatric symptoms and comorbidities. Clinicians should constantly consider the possibility of ADHD when evaluating adult patients. Most importantly, greater emphasis should be placed on improving adherence to pharmacological treatment rather than on the relatively minimal risk of medication abuse or misuse. Enhancing treatment adherence in adults with ADHD has the potential to significantly improve functioning across multiple domains."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Recent Advances in Pharmacological Management of Autism: A Narrative Review. (PubMed, Cureus) - "Medications, including US Food and Drug Administration (FDA)‑approved antipsychotics such as risperidone and aripiprazole, are used to manage comorbid irritability and aggression, stimulants and non‑stimulants (e.g., methylphenidate, atomoxetine, clonidine, guanfacine) to treat ADHD-like symptoms, and melatonin for sleep disturbances. Other off‑label agents like selective serotonin reuptake inhibitor (SSRIs) for anxiety/obsessive compulsive disorder (OCD), anticonvulsants or mood stabilizers for mood dysregulation. Emerging compounds such as intranasal oxytocin and N‑acetylcysteine are under investigation but have not yet been formally approved. The future of ASD care hinges on the development of objective, biologically based diagnostic tools ranging from EEG and neuroimaging biomarkers to proteomic and metabolomic panels that could enable early, precise identification and guide personalized treatment strategies."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Depression • Epilepsy • Genetic Disorders • Immunology • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Sleep Disorder

Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study. (PubMed, Lancet Reg Health Eur) - "We estimated the prevalence and incidence of methylphenidate, dexamphetamine, lisdexamfetamine, atomoxetine and guanfacine use among individuals aged 3 years and older. Understanding the utilisation of ADHD medications can provide useful information in monitoring use, as well as for anticipation and planning to minimise potential shortages. European Medicines Agency."

Journal • Observational data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Chronic Administration of Atomoxetine and Methylphenidate Induces Differential Alterations in the Hippocampus and Striatum of Young Rats. (PubMed, Neurotox Res) - No abstract available

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Connecting the dots and finding the way forward: Pharmacological, neuromodulatory, and psychotherapeutic interventions for the complex treatment of adult ADHD. (PubMed, Pharmacol Ther) - "Treatment emphasizes multimodal approaches, with stimulants as first-line pharmacotherapy due to their superior efficacy over non-stimulants like atomoxetine and viloxazine. Novel agents in development, such as centanafadine triple reuptake inhibitor and solriamfetol target core symptoms and comorbidities, showing promising phase III results...Psychotherapeutic options, particularly cognitive-behavioral therapy (CBT)-based interventions, improve symptom management and emotional regulation, often as adjuncts to medication. The review highlights the need for personalized strategies addressing adherence, comorbidity, and long-term outcomes, emphasizing integrated care to mitigate ADHD's lifelong impact."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

Populational pharmacokinetics of methylphenidate hydrochloride extended-release tablets in Chinese school-age children with attention-deficit/hyperactivity disorder (ChiCTR) - P=N/A | N=60 | Completed | Sponsor: Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University

New trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Drug-related suicidal events in children and teenagers: Age-stratified insights from FAERS. (PubMed, Leg Med (Tokyo)) - "Across FAERS youth suicide reports, drug-associated fatality risk varies markedly by drug, surges in mid- to late adolescence, diverges by sex and shifts at both age extremes. These heterogeneities underscore the need for age-appropriate pharmacovigilance and trial strategies rather than direct extrapolation from adult data, particularly regarding the safety of drugs associated with suicide."

Journal • Pediatrics

Atomoxetine for encopresis in children with autism spectrum disorder: Report of 4 cases. (PubMed, Psychiatr Danub) - No abstract available

Journal • Autism Spectrum Disorder • Genetic Disorders

Efficacy and safety of atomoxetine in the treatment of ADHD in children and adolescents: a systematic review. (PubMed, Front Child Adolesc Psychiatry) - "Atomoxetine demonstrated comparable efficacy to methylphenidate in reducing ADHD symptoms. Continued research, especially long-term studies, is necessary to confirm its efficacy across different patient subgroups. Identifier CRD420251152121."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fatigue • Psychiatry

Biomarkers for predominantly inattentive ADHD: potential involvement of Wnt/β-catenin/integrin signaling in a spontaneously hypertensive rat. (PubMed, Genes Genomics) - "Dysregulation of Wnt/β-catenin/integrin signaling may contribute to the ADHD pathophysiology. Concordant upregulation of Ctnnβ1 and Itgβ1 in brain and peripheral blood may support their potential as peripheral biomarkers of ADHD. Responsiveness of these genetic markers to atomoxetine treatment indicates potential value for treatment monitoring and supports targeting this pathway in future therapeutic strategies."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry • ITGB1

Differential working memory changes following methylphenidate in medication-naive and medication-experienced adults with ADHD. (PubMed, PCN Rep) - "A sensitivity analysis excluding atomoxetine-experienced participants showed a preserved effect size but trend-level significance (q = 0.061). Rather than reflecting a purely pharmacological effect, these patterns may involve a combination of baseline cognitive differences, learned cognitive strategies, and pre-existing individual characteristics. These preliminary findings highlight the importance of considering treatment history in clinical practice and research."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Update on pharmacogenetics in pediatrics. (PubMed, An Pediatr (Engl Ed)) - "Drug-gene pairs with greater use in pediatrics are presented in more detail, such as proton pump inhibitors and CYP2C19, Abacavir, allopurinol, carbamazepine, oxcarbazepine, and phenytoin with HLA-A and HLA-B genes, voriconazole and CYP2C19, tacrolimus and CYP3A5, aminoglycosides and MT-RNR1, thiopurines and TMPT/NUDT15, or atomoxetine and CYP2D6. Despite current limitations, the use of pharmacogenetics in pediatrics can and should be implemented in those cases where regulatory agencies and/or scientific societies recommend it."

Biomarker • Journal • Pediatrics • CYP2C19 • CYP3A5 • HLA-B • NUDT15

Drug-induced phospholipidosis of the kidney suspected to be caused by atomoxetine. (PubMed, J Pathol Transl Med) - "When zebra bodies are observed, clinicians should consider DIP caused by cationic amphiphilic drugs alongside Fabry disease. Atomoxetine meets the structural criteria for inducing DIP, and awareness of this potential complication is essential."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fabry Disease • Fibrosis • Genetic Disorders • Immunology • Inflammation • Lysosomal Storage Diseases • Metabolic Disorders • Psychiatry • Rare Diseases • Renal Disease

STAM1-deficient mice exhibit an attention-deficit/hyperactivity disorder-like phenotype. (PubMed, Biochem Biophys Res Commun) - "The ADHD therapeutic agent atomoxetine ameliorated ADHD-like impulsivity observed in STAM1-deficient mice; STAM1-deficient mice treated with the dopamine D4 receptor antagonist clozapine, but not the dopamine D2 receptor antagonist haloperidol, showed reduced ADHD-like impulsivity. These results indicate that STAM1-deficient mice show ADHD-like symptoms, suggesting the possibility of a new ADHD animal model. Moreover, clozapine may be a new therapeutic agent for ADHD."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Psychiatry • DRD2

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease (clinicaltrials.gov) - P1 | N=23 | Completed | Sponsor: Hubert Fernandez | Recruiting ➔ Completed | N=42 ➔ 23 | Trial completion date: Dec 2028 ➔ Dec 2025 | Trial primary completion date: Dec 2027 ➔ Dec 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov) - P3 | N=60 | Not yet recruiting | Sponsor: Radboud University Medical Center

New P3 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Prescribed Drugs and Interpersonal Violence: A Case-Non-Case Study in the Spanish Pharmacovigilance Database. (PubMed, Pharmaceuticals (Basel)) - "Mostly drugs reported were montelukast, levetiracetam, bupropion, donepezil, perampanel, quetiapine, fluoxetine, and lorazepam. A statistically significant association/disproportion in the notification has been found in the reporting of interpersonal violence and different drugs according to the literature, notably atomoxetine, perampanel, memantine, donepezil, montelukast and methylphenidate. The results highlight that interpersonal violence, while rare, could occur as a clinically relevant adverse reaction to a small subset of medications. They underscore the importance of careful prescribing, especially in vulnerable populations and in individuals with a history of psychiatric disorders."

Adverse events • Journal • CNS Disorders • Mental Retardation • Psychiatry

Priapism associated with atomoxetine use (PubMed, Tijdschr Psychiatr) - "The literature includes several cases describing atomoxetine-induced priapism in children and adolescents. This case, in which an adult male experienced priapism as a side effect of atomoxetine, highlights the importance of being vigilant for this potential complication when prescribing the drug, including in adult patients."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pain • Psychiatry

Effectiveness of Pharmacological Treatments for Adult ADHD on Psychiatric Comorbidity: A Systematic Review. (PubMed, J Clin Med) - "This systematic review evaluated the effectiveness of commonly prescribed medications for adult ADHD (methylphenidate, atomoxetine, bupropion, and lisdexamfetamine) on comorbid mood, anxiety, personality, and substance use disorders. Tricyclic antidepressants were also included in the search strategy; however, no eligible adult studies assessing imipramine or desipramine in patients with ADHD and psychiatric comorbidity were identified...While targeted improvements may occur in specific domains, the evidence base is insufficient to define optimal long-term strategies for adults with ADHD and complex comorbidity. Rigorous, longitudinal studies are needed to clarify medication effects on distinct comorbid profiles and to inform integrated treatment planning."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry

Drug Development. (PubMed, Alzheimers Dement) - "We present a practical approach to prioritising repurposed drugs to evaluate in the context of clinical AD. We would like to thank our patient and public contributors and the wider investigator team."

Journal • Alzheimer's Disease • CNS Disorders • Psychiatry